SEMA / IGF-1 LR3Check methods and identity
What binding-protein measurements tell us about semaglutide
2 numbered sourcesSource years 1992, 2025
Short amino-acid chains connected by peptide bonds are peptides. They can signal through receptors or interact with other proteins. Semaglutide activates the GLP-1 receptor. IGF-1 LR3 is a modified insulin-like growth factor protein with altered binding properties. An older human study measured IGF-binding proteins during semaglutide treatment. It helps explain the difference between measuring a change in the body’s growth-factor system and administering a growth-factor analog. [1, 2]
The investigators followed 34 people with type 2 diabetes who were already receiving metformin. Some received semaglutide and some received sitagliptin. The study also included a matched comparison group. Researchers measured several binding proteins over a year. They reported an increase in IGFBP-1 during treatment with either drug. The measured level of another related protein, IGFBP-rp1, did not change significantly with either treatment. These measurements concern proteins already circulating in the participants. [1]
Binding proteins can affect how much IGF-1 is available to receptors. Older cell research describes IGF-1 LR3 as having lower affinity for IGF-binding proteins than ordinary IGF-1. These two observations answer separate questions. One concerns changes in the concentration of proteins in the blood during semaglutide treatment. The other concerns how a modified growth-factor molecule interacts with such proteins in laboratory research. [1, 2]
The one-year study did not administer IGF-1 LR3 or measure the outcome of using it with semaglutide. It therefore cannot tell us whether that combination would change growth-factor signaling, body composition or adverse events. The available study is evidence about blood measurements during treatment with the medications it actually examined. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
